Adagene Inc. has announced a strategic investment of up to $25 million from Sanofi to support the clinical development of muzastotug (ADG126), an anti-CTLA-4 SAFEbody. The company plans to use the proceeds to conduct a randomized phase 2 trial in microsatellite stable colorectal cancer (MSS CRC). Additionally, Adagene will supply muzastotug to Sanofi for a phase 1/2 clinical trial involving over 100 patients with advanced solid tumors to assess safety, efficacy, pharmacokinetics, and biomarker data in combination with other anticancer therapies. The results of these clinical trials have not yet been presented.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.